Antimicrobial Wound Matrix

Microlyte® Matrix absorbs wound fluid and transforms into a bioresorbable gel that intimately contours to the underlying wound bed to maintain a physiologically moist microenvironment. Silver in the matrix kills 99.99% of bacteria for several days while employing up to 100 times less silver than cover dressings or topical solutions. It reduces the risk of silver toxicity and staining, making it safe for use at the onset of any wound management plan, including burns, donor sites, diabetic ulcers and pressure sores.

Antibiofilm Wound Matrix

Based on our Microlyte® Matrix platform, we are developing an ultrathin, bioresorbable wound matrix that synergistically employs the antibiofilm transition metal gallium and antimicrobial silver to disrupt biofilms under wound dressings. The matrix will prevent formation of bacterial biofilms on a wound-bed and will kill bacteria living inside established biofilms. The product will be optimal for application at the onset of a wound treatment plan for wounds at risk of infection, and for chronic wounds with signs of biofilms.

Anesthetic Wound Matrix

Exploiting the Microlyte® Matrix technology’s ability for sustained release of therapeutics, we are developing a product that will increase the retention time of anesthetics in the localized microenvironment of the wound bed, increasing retention time of anesthetic to relieve local pain in surgical and chronic wounds. The matrix will reduce up to 100 times the amount of anesthetics required to relieve local pain (compared to topical or oral formulations), potentially circumventing risks of side-effects or addiction in patients with severe or chronic wounds. 



Antimicrobial wound matrix market


Wound infection under biologic dressings


Patients with burns and chronic ulcers in the US and EU


Growth rate for antimicrobial wound dressings market